Celator Pharmaceuticals, Inc.;Oregon Health & Science University; Inc.;Celator Pharmaceuticals
发明人:
Gordon, Max,Tardi, Paul,Tyner, Jeffrey,Mayer, Lawrence
申请号：
AU2016353163
公开号：
AU2016353163A1
申请日:
2016.11.10
申请国别(地区):
AU
年份:
2018
代理人:
摘要：
Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.
